ArticleWorld journal of urology2025
From bladder to kidney: calprotectin as a novel marker for differentiation of urinary tract infection.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- S100A8/A9 in Kidney Diseases: Mechanisms, Spatiotemporal Regulation, Biomarker Potential, and Therapeutic Implications.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infections (UTIs) are common diseases in the community that can lead to significant morbidity and mortality. UTIs can be classified as cystitis or pyelonephritis based on their location. Calprotectin is a protein released from monocytes and neutrophils that plays a role in the inflammatory response and antimicrobial defense. In this study it was aimed to investigate the diagnostic potential of calprotectin in distinguishing acute cystitis from acute pyelonephritis by evaluating serum and urine calprotectin levels in patients with UTI.
methodsThe study included adults aged 18 years and older who were admitted to our clinic with UTIs, including both pyelonephritis and cystitis, as well as healthy volunteers who served as the control group, between January 2024 and October 2024. In addition to routine biochemical and hematological tests, serum and urine calprotectin levels were measured. Data were analyzed using SPSS 21.0.
resultsA total of 88 participants were included in the study: 30 patients with pyelonephritis, 30 patients with cystitis, and 28 healthy controls. Female gender was predominant in all groups. Serum calprotectin levels were higher in patients with pyelonephritis and cystitis compared to the healthy control group (p < 0.001). Urinary calprotectin levels were significantly higher in the cystitis group compared to the pyelonephritis and healthy controls (p < 0.001). There was a positive and significant correlation between serum calprotectin and C-reactive protein (CRP) and procalcitonin (PCT) levels.
conclusionsOur study suggests that calprotectin may be a useful biomarker in the diagnosis of UTI and the differentiation between lower and upper urinary tract infections, and sheds light on future large-scale studies.
Indexed as
Identifiers
41379367What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.